Related Experiment Video

Updated: Jul 5, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Interindividual variability in metformin pharmacokinetics in pediatric patients

Anoud Sameer Ailabouni1,2, Kelsee Halpin3,4, Erin C Boone5

  • 1Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.

Pediatric Research
|July 3, 2026
PubMed

Insights

Metformin pharmacokinetics in children shows significant variability. Dosing can be optimized using total body weight, kidney function (eGFR), and specific genetic variants (OCT2/3) for improved safety and efficacy.

Area of Science:

  • Pharmacology
  • Pediatric Endocrinology
  • Genetics

Background:

  • Metformin is a first-line treatment for type 2 diabetes in children, with increasing off-label use.
  • Interindividual variability in pediatric metformin pharmacokinetics is not well understood.
  • Metformin transport involves organic cation transporters (OCTs) and multidrug and toxin extrusion (MATE) transporters.

Purpose of the Study:

  • To characterize metformin pharmacokinetics in pediatric patients.
  • To investigate the influence of covariates, including genetic variants, on metformin pharmacokinetics.

Main Methods:

  • A 12-hour pharmacokinetic study was conducted in 36 pediatric patients (ages 7-21).
  • Non-compartmental and population pharmacokinetic models were used for data analysis.
  • The association of OCT and MATE genetic variants with metformin absorption and elimination was examined.

Main Results:

  • Dose-normalized metformin exposure varied 3.3-fold among children.
  • Pediatric renal clearance exceeded that of adults.
  • Total body weight and eGFR significantly impacted oral clearance.
  • Specific OCT2 and OCT3 genetic variants were associated with metformin oral clearance, secretary clearance, and absorption rate.

Conclusions:

  • Metformin pharmacokinetics in children are highly variable.
  • Total body weight, eGFR, and OCT2/3 genetic variants are key factors influencing metformin pharmacokinetics.
  • Optimizing metformin dosing based on these factors can enhance pediatric patient safety and treatment efficacy.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...